Such prospective and retrospective studies consistently report that the use of COCs significantly decreases the risk of ovarian and endometrial cancer
Methods: One hundred and fifty patients with endometrial cancer
who were admitted to Binzhou People's Hospital, Shandong, China, between June 2013 and July 2014, were enrolled and set as an endometrial cancer
group; another one hundred patients with benign uterine diseases and one hundred healthy females were also enrolled.
The Endometrial Cancer
therapeutics market is poised to reach approximately USD 27bn by 2023, according to a report from Dublin-based Research and Markets.
occurs in the lining of the uterus and is the most common cancer in the female reproductive organ, (https://www.
Given these issues, the sentinel lymph node (SLN) technique strikes a balance between the risks and benefits of lymph node evaluation in endometrial cancer
Biopharmaceutical company Xenetic Biosciences (OTCQB:XBIO) announced on Friday that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for the product candidate, Virexxa (sodium cridanimod), to initiate its Phase 2 Clinical Trial of Virexxa in endometrial cancer
, the most common malignancy of the female genital tract and represents a major health concern, as overall five-year survival rates have not improved over the past three decades.
Additionally, the report provides an overview of key players involved in therapeutic development for Endometrial Cancer
and features dormant and discontinued projects.
David Dodd, Chairman and CEO of Aeterna Zentaris, commented, This positive second recommendation from the DSMB is an important milestone since it supports our continuation of the ZoptEC Phase 3 trial in endometrial cancer
until its completion.
Instead, combined estrogen plus progestin hormonal therapy is prescribed routinely for postmenopausal women with a uterus to reduce their risk of endometrial cancer
Adds Russell Broaddus, professor of pathology: 'The identification of this second cluster of patients with endometrial cancer
helps to refute longstanding teachings that young, obese patients universally have endometrial cancers
that are estrogen-driven and thus have a good prognosis.
Crude incidence of endometrial cancer
was 12 per 10,000 person-years for nonusers and 8 per 10,000 years for bisphosphonate users (bisphosphonate users: hazard ratio, 0.
which arises in the lining of the uterus accounts for nearly 50 percent of gynecologic cancers diagnosed in the United States and it is the fourth most common malignancy in women and the eighth most common cause of cancer death.